ViroGates A/S (CPH:VIRO)
10.80
+0.50 (4.85%)
May 6, 2026, 2:02 PM CET
ViroGates Revenue
In the year 2025, ViroGates had annual revenue of 8.90M DKK with 24.67% growth. ViroGates had revenue of 2.36M in the quarter ending December 31, 2025, with 50.70% growth.
Revenue
8.90M
Revenue Growth
+24.67%
P/S Ratio
10.74
Revenue / Employee
1.27M
Employees
7
Market Cap
95.60M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 8.90M | 1.76M | 24.67% |
| Dec 31, 2024 | 7.14M | 155.00K | 2.22% |
| Dec 31, 2023 | 6.99M | -8.21M | -54.02% |
| Dec 31, 2022 | 15.20M | 6.95M | 84.27% |
| Dec 31, 2021 | 8.25M | 2.89M | 54.03% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novo Nordisk | 309.06B |
| Coloplast | 27.89B |
| Genmab | 23.66B |
| ALK-Abelló | 6.56B |
| Gubra | 2.64B |
| Scandinavian Medical Solutions | 245.44M |
| BioPorto | 40.29M |
| Monsenso | 8.91M |
ViroGates News
- 5 weeks ago - ViroGates Earnings Call Transcript: Q4 2025 - Transcripts
- 6 months ago - ViroGates Earnings Call Transcript: Q3 2025 - Transcripts
- 1 year ago - ViroGates Earnings Call Transcript: Q1 2025 - Transcripts
- 1 year ago - ViroGates Earnings Call Transcript: Q4 2024 - Transcripts
- 1 year ago - ViroGates Earnings Call Transcript: Q3 2024 - Transcripts
- 1 year ago - ViroGates Earnings Call Transcript: Q2 2024 - Transcripts
- 2 years ago - ViroGates Earnings Call Transcript: Q1 2024 - Transcripts
- 2 years ago - ViroGates Earnings Call Transcript: Q4 2023 - Transcripts